Raymond James Financial
LRMR icon

Raymond James Financial’s Larimar Therapeutics LRMR Stock Holding History

Raymond James Financial’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,000
Closed -$23.1K – 5961
2025
Q2 		$23.1K Buy
+8,000
New +$18.5K ﹤0.01% 5541

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Raymond James Financial's LRMR Position: Q3 2025 in Review

Raymond James Financial sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 8,000 shares — an estimated $23.1K sold.

Raymond James Financial first reported a position in LRMR in Q2 2025 and held it in 1 quarter. The position peaked at $23.1K in Q2 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • Raymond James Financial reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 8,000 Larimar Therapeutics shares in Q3 2025, an estimated $23.1K.
  • Raymond James Financial first reported a position in Larimar Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Larimar Therapeutics position peaked at $23.1K in Q2 2025.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.